Polpharma Biologics is a group of biopharmaceutical companies focused on the development and manufacturing of biopharmaceuticals and biosimilars for global markets. Its Switzerland-based biosimilars platform manages the entire value chain—from product selection and investment allocation through development and commercialization—ensuring efficient progression from concept to launch in close collaboration with global partners. The company’s biosimilar portfolio spans multiple programs at various stages of development, from early-stage research to commercialization. Its international team brings deep expertise across program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Through Polpharma Biologics partnerships with trusted CDMOs, Polpharma Biologics delivers end-to-end biosimilar solutions, from cell line development to finished products, across key therapeutic areas. Polpharma Biologics is committed to accelerating access to biologic therapies worldwide by maintaining a robust and expanding pipeline of biosimilars.